{"groups":[{"description":"Patients undergo standard fractionation radiotherapy (IMRT or 3D CRT) once daily, 5 days a week, for 7 weeks. Patients receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.\n\ncisplatin: Given IV\n\n3-dimensional conformal radiation therapy: Patients undergo radiotherapy\n\nintensity-modulated radiation therapy: Patients undergo radiotherapy","id":"FG000","title":"Cisplatin"},{"description":"Patients undergo accelerated fractionation radiotherapy (IMRT or 3D CRT) once or twice daily, 5 days a week, for 6 weeks. Patients receive panitumumab IV over 30-90 minutes 1 week prior to and on days 15 and 36 of radiotherapy.\n\npanitumumab: Given IV\n\n3-dimensional conformal radiation therapy: Patients undergo radiotherapy\n\naccelerated radiation therapy: Patients undergo accelerated fractionation radiotherapy\n\nintensity-modulated radiation therapy: Patients undergo radiotherapy","id":"FG001","title":"Panitumumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"}],"type":"No treated"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"160"},{"groupId":"FG001","numSubjects":"160"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"156"},{"groupId":"FG001","numSubjects":"159"}],"comment":"Only treated patients were evaluated for adverse event.","type":"Received Protocol Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"156"},{"groupId":"FG001","numSubjects":"159"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}